Technology
We are developing a unique set of molecules to treat vascular related diseases, such as Primary Open Angle Glaucoma, Pediatric Glaucoma, Cystic Kidney Disease, and Inflammation via our proprietary research platform.
Research
Our primary indication, MAN-01, is for treatment of Primary Open Angle Glaucoma, wherein we are developing a small molecule in the form of an easy to administer eye drop to reduce intra-ocular eye pressure (IOP), a key risk factor in the progression of Glaucoma.
